Key Points
- Director Robert More sold 10,000 shares of Tyra Biosciences on December 19 at an average price of $25, generating $250,000 in proceeds and reducing his stake by about 0.26% to 3,823,425 shares.
- Tyra trades near $25.51 with a market cap of $1.36 billion, negative trailing EPS, and is trading above its 50‑ and 200‑day moving averages ($18.17 and $13.66) within a 52‑week range of $6.42–$25.88.
- Institutional ownership is high (84.14%), and analysts maintain a consensus "Moderate Buy" rating with an average target price of about $33.17.
Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Robert More sold 10,000 shares of the company's stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the transaction, the director owned 3,823,425 shares in the company, valued at $95,585,625. This represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Tyra Biosciences Stock Performance
Tyra Biosciences stock opened at $25.51 on Friday. The company has a market capitalization of $1.36 billion, a PE ratio of -13.64 and a beta of 1.09. The company has a 50 day moving average price of $18.17 and a 200-day moving average price of $13.66. Tyra Biosciences, Inc. has a fifty-two week low of $6.42 and a fifty-two week high of $25.88.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). On average, analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in TYRA. Commodore Capital LP grew its stake in Tyra Biosciences by 8.9% in the 3rd quarter. Commodore Capital LP now owns 3,375,000 shares of the company's stock valued at $47,216,000 after acquiring an additional 275,000 shares during the period. Vestal Point Capital LP lifted its stake in Tyra Biosciences by 190.9% in the 1st quarter. Vestal Point Capital LP now owns 2,879,829 shares of the company's stock valued at $26,782,000 after buying an additional 1,889,829 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Tyra Biosciences by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company's stock worth $21,267,000 after buying an additional 118,492 shares in the last quarter. Balyasny Asset Management L.P. raised its holdings in Tyra Biosciences by 45.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 846,585 shares of the company's stock valued at $11,844,000 after acquiring an additional 263,199 shares during the last quarter. Finally, Sio Capital Management LLC raised its holdings in Tyra Biosciences by 94.5% in the 2nd quarter. Sio Capital Management LLC now owns 810,274 shares of the company's stock valued at $7,754,000 after acquiring an additional 393,657 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on TYRA shares. Oppenheimer reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, September 10th. Raymond James Financial began coverage on Tyra Biosciences in a research note on Tuesday, September 2nd. They issued a "strong-buy" rating and a $35.00 target price for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, August 22nd. Finally, Wedbush lifted their target price on Tyra Biosciences from $30.00 to $37.00 and gave the stock an "outperform" rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $33.17.
View Our Latest Stock Report on TYRA
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.
The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
